MICHELLE GARRETT: Open Payments
NPI 1235894262 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,607 in 166 payments from 16 companies in 2025. Trend: 2023 $1,135 · 2024 $1,298 · 2025 $2,607
Food & beverage: $2,607
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $490 |
| Vanda Pharmaceuticals Inc. | 26 | $440 |
| ABBVIE INC. | 18 | $316 |
| Teva Pharmaceuticals USA, Inc. | 22 | $281 |
| Lundbeck LLC | 14 | $236 |
| E.R. Squibb & Sons, L.L.C. | 10 | $189 |
| Alkermes, Inc. | 18 | $153 |
| Axsome Therapeutics, Inc. | 9 | $141 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
Products named: CAPLYTA, FANAPT, REXULTI, VRAYLAR, AUSTEDO XR, COBENFY, ARISTADA, Auvelity.
Industry payments across MO — which companies pay providers there.
